Redwood Pharma AB is a company whose mission is to develop new ophthalmic pharmaceutical therapies where there are large and unmet market needs. It has in-licensed, IntelliGel, a proprietary and patented hydrogel drug delivery platform technology that will reduce dosages, dosing-frequency and, thereby, potential systemic toxicities of active pharmaceutical ingredients.
The Company’s lead development product is a new therapy to treat chronic Dry Eye Disease (DED) in post-menopausal women. With an ageing population, DED affects more and more people hindering many in their daily activities such as reading, using a computer and driving an automobile.
Redwood Pharma to execute New Rights Issue and takes important step in securing further financing